Denali Therapeutics upgraded by Cantor Fitzgerald
$DNLI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Cantor Fitzgerald upgraded Denali Therapeutics from Neutral to Overweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | Neutral → Overweight | Cantor Fitzgerald | |
| 3/7/2025 | $41.00 → $33.00 | Overweight | Morgan Stanley |
| 2/11/2025 | $31.00 | Buy | Deutsche Bank |
| 1/7/2025 | $31.00 | Outperform | Robert W. Baird |
| 1/3/2025 | Outperform | William Blair | |
| 12/16/2024 | $37.00 | Hold → Buy | Stifel |
| 10/10/2024 | Mkt Perform | Raymond James | |
| 10/7/2024 | Overweight → Neutral | Cantor Fitzgerald |
8-K - Denali Therapeutics Inc. (0001714899) (Filer)
10-Q - Denali Therapeutics Inc. (0001714899) (Filer)
8-K - Denali Therapeutics Inc. (0001714899) (Filer)
4 - Denali Therapeutics Inc. (0001714899) (Issuer)
3 - Denali Therapeutics Inc. (0001714899) (Issuer)
3 - Denali Therapeutics Inc. (0001714899) (Issuer)